Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Daniil, F. Malli, M. Dimadi, K. Antoniou, A. Tzouvelekis, F. Drakopanagiotakis, F. Kokkinis, G. Margaritopoulos, K. Manika, D. Bouros, D. Papakosta (Larissa, Athens, Heraklion, , Thessaloniki, Greece). Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group. Eur Respir J 2010; 36: Suppl. 54, 785

Member's Comments

No comment yet.

Related content which might interest you: Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis Source: Eur Respir J 2013; 42: 230-238 Year: 2013 Gender perspective in Interstitial Lung Diseases (ILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Hypersentivity pneumonitis in an Interstitial Lung Disease Unit, 5 years’ experience Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used Source: International Congress 2017 – Rare diseases Year: 2017 Clinical features of four children with pulmonary alveolar proteinosis Source: International Congress 2014 – ILDs 5 Year: 2014 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014 Airway centered interstitial fibrosis – An under-recognized type of idiopathic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014